16 April 2015Wilson Therapeutics announces presentation of WTX101-201 Phase 2 Study at The Easl 50th International Liver Congress 2015
Wilson Therapeutics AB, a development stage biopharmaceutical company, today announced that a poster of the company’s ongoing Phase 2 clinical trial for WTX101-201 will be presented at the upcoming annual meeting of the European Association for the Study of the Liver (EASL), or the 50th International Liver Congress 2015, taking place in Vienna April 22-26. The poster, titled “WTX101-201: Phase 2 Study of Bis-choline Tetrathiomolybdate in Newly Diagnosed Wilson Disease Patients,” will be presented in the Clinical Trials in Progress session on April 25.
16 April 2015Sequana Medical signs collaboration agreement with Fresenius Medical Care for the marketing and distribution of the alfapump® system.
Sequana Medical, a Swiss-based medical device company, announced today that it has entered into an agreement with Fresenius Medical Care to commercialize its innovative alfapump system.
19 March 2015Creabilis’ CT327 Phase 2b Data Published in Acta Dermato-Venereologica, Strengthens Scientific Advisory Board
Creabilis Ltd, the dermatology company with the most advanced targeted topical treatment in development for chronic pruritus (itch), announces today that it has published positive Phase 2b clinical data for its novel TrkA kinase inhibitor CT327 in Acta Dermato-Venereologica, one of the pre-eminent international peer-review journals in dermatology.
5 February 2015
InDex Pharmaceuticals today announced that the Board of Directors has named Peter Zerhouni as new CEO. Peter Zerhouni comes from a position as CEO at Diamyd Medical AB where he has been instrumental in bringing the company’s business and clinical trials forward. He will succeed Jesper Wiklund, who has led the company since 2011.
3 February 2015InDex Pharmaceuticals to present results from the COLLECT trial at the 10th Congress of the European Crohn’s and Colitis Organisation
InDex Pharmaceuticals today announced that results from COLLECT, a clinical study of the toll-like receptor 9 (TLR9) agonist Kappaproct as an add-on therapy for patients with moderate to severe, chronic active Ulcerative Colitis, will be subject to an oral presentation at the 10th Congress of the European Crohn’s and Colitis Organisation (ECCO). The congress is to be held in Barcelona, Spain on February 18-21, 2015.